4 Februari 2015
4 February 2015
P.U. (A) 17

WARTA KERAJAAN PERSEKUTUAN

FEDERAL GOVERNMENT GAZETTE

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2015

POISONS (AMENDMENT OF POISONS LIST) ORDER 2015

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2015

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2015**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

(i) dengan menggantikan butiran "Abrisentan" dengan butiran "Ambrisentan";

(ii) dengan memasukkan selepas butiran "Alphadolone acetate" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Alpha-Phenylacetoacetonitrile (APAAN)	-	-	-	-	All preparations";	

(iii) dengan menggantikan butiran “Amilsulpride” dengan butiran “Amisulpride”;

(iv) dengan menggantikan butiran “Anistreplace” dengan butiran “Anistreplase”;

(v) dalam butiran “Antihistamines; the following:”—

(A) dengan menggantikan butiran “Dimenhydramine” dengan butiran “Dimenhydrinate”; dan

(B) dengan menggantikan butiran “Levocetrizine” dengan butiran “Levocetirizine”;

(vi) dengan menggantikan butiran “Calcium polysterene” dengan butiran “Calcium polystyrene”;

(vii) dengan memasukkan selepas butiran “Camylofine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
“Canakinumab	-	All preparations”;				

(viii) dengan memasukkan selepas butiran "Cerivastatin; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Certolizumab	-	All preparations";				

(ix) dengan memasukkan selepas butiran "2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"1,3-Dimethylamylamine (DMAA)	All preparations";					

(x) dengan memasukkan selepas butiran "Dinitrothymols" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Diphenidol hydrochloride	-	-	All preparations";			

(xi) dengan memotong butiran "Fexofenadine; its salt" dan butir-butir yang berhubungan dengannya;

(xii) dengan memasukkan selepas butiran "Gallamine; its salts; its quarternary compounds" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Gamma Butyrolactone	-	-	-	-	All preparations unless exempted	When use as food additive in food";

(xiii) dengan memasukkan selepas butiran "Indomethacin; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Infliximab	-	All preparations";				

(xiv) dengan menggantikan butiran "Lanthanum" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lanthanum carbonate	-	All preparations for therapeutic use";				

(xv) dengan memasukkan selepas butiran "Mipomersen sodium" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Mirabegron	-	All preparations";				

(xvi) dalam butiran "Natamycin", dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Natamycin	-	-	All preparations unless exempted	-	-	Natamycin when use as food additive in food";

(xvii) dalam butiran "Potassium hydroxide", dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Potassium hydroxide	-	-	-	-	12% and over unless exempted	Under 12%, accumulators, batteries or when use as food additive in food";

(xviii) dalam butiran "Sodium hydroxide", dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Sodium hydroxide	-	-	All preparations for therapeutic or diagnostic use	-	All preparations containing 12% and over other than those in Part I or exempted and subject to the provisions of Poisons (Sodium Hydroxide) Regulations 1962	Under 12%; sodium hydroxide when use as food additive in food";

(xix) dengan memotong butiran "Terfenadine" dan butir-butir yang berhubungan dengannya; dan

(xx) dengan memasukkan selepas butiran "Todrazoline; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Tofacitinib	-	All preparations"; dan				

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai "**Anticholinergics:**"—

(A) dengan memasukkan selepas butiran "Diethazine; its salts" butiran "Diphenidol hydrochloride"; dan

(B) dengan memasukkan selepas butiran "Methixene; its salts" butiran "Mirabegron";

(ii) dalam senarai "**Antihistamines:**"—

(A) dengan memasukkan selepas butiran "3-Dibutylaminoethyl-4, 5, 6-trihydroxy-1-isobenzofuranone" butiran "Dimenhydrinate"; dan

(B) dengan menggantikan butiran "Levocetrizine" dengan butiran "Levocetirizine";

(iii) dalam senarai "**Antineoplastic agents and Immunosuppressants:**"—

(A) dengan memasukkan selepas butiran "Cabazitaxel" butiran "Canakinumab";

(B) dengan memasukkan selepas butiran "Carmustine; its salts" butiran "Certolizumab";

(C) dengan memasukkan selepas butiran "Idarubicin" butiran "Infliximab"; dan

(D) dengan memasukkan selepas butiran "Tocilizumab" butiran "Tofacitinib";

(iv) dalam senarai "**Cardio drugs:**"—

(A) dengan menggantikan butiran "Abrisentan" dengan butiran "Ambrisentan"; dan

(B) dengan menggantikan butiran "Anistreplace" dengan butiran "Anistreplase";

(v) dalam senarai "**Industrial and laboratory poisons:**"—

(A) dengan memasukkan selepas butiran "Acetyl chloride" butiran "Alpha-Phenylacetoacetonitrile (APAAN)"; dan

(B) dengan memasukkan selepas butiran "Formaldehyde" butiran "Gamma Butyrolactone";

(vi) dalam senarai "**Sympathomimetic amines:"**, dengan memasukkan selepas butiran "Atomoxetine; its salts" butiran "1,3- Dimethylamylamine (DMAA)";

(vii) dalam senarai "**Tranquillisers:"**, dengan menggantikan butiran "Amilsulpride" dengan butiran "Amisulpride"; dan

(viii) dalam senarai "**Miscellaneous:**"—

(A) dengan menggantikan butiran “Calcium polysterene” dengan butiran “Calcium polystyrene”; dan

(B) dengan menggantikan butiran “Lanthanum” dengan butiran “Lanthanum carbonate”.

Dibuat 26 Januari 2015
[KK(R)608(14); PN(PU2)172/XIII]

DATUK SERI DR. S. SUBRAMANIAM
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2015

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2015**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

(i) by substituting for the item "Abrisentan" the item "Ambrisentan";

(ii) by inserting after the item "Alphadolone acetate" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Alpha-Phenylacetoacetonitrile (APAAN)	-	-	-	-	All preparations";	

(iii) by substituting for the item "Amilsulpride" the item "Amisulpride";

(iv) by substituting for the item "Anistreplace" the item "Anistreplase";

(v) in the item "Antihistamines; the following:"—

(A) by substituting for the item "Dimenhydramine" the item "Dimenhydrinate"; and

(B) by substituting for the item "Levocetrizine" the item "Levocetirizine";

(vi) by substituting for the item "Calcium polysterene" the item "Calcium polystyrene";

(vii) by inserting after the item "Camylofine; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Canakinumab	-	All preparations";				

(viii) by inserting after the item "Cerivastatin; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Certolizumab	-	All preparations";				

(ix) by inserting after the item "2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"1,3-Dimethylamylamine (DMAA)	All preparations";					

(x) by inserting after the item "Dinitrothymols" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Diphenidol hydrochloride	-	-	All preparations";			

(xi) by deleting the item "Fexofenadine; its salt;" and the particulars relating to it;

(xii) by inserting after the item "Gallamine; its salts; its quarternary compounds" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Gamma Butyrolactone	-	-	-	-	All preparations unless exempted	When use as food additive in food";

(xiii) by inserting after the item "Indomethacin; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Infliximab	-	All preparations";				

(xiv) by substituting for the item "Lanthanum" and the particulars relating to it the following particulars:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lanthanum carbonate	-	All preparations for therapeutic use";				

(xv) by inserting after the item "Mipomersen sodium" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Mirabegron	-	All preparations";				

(xvi) in the item "Natamycin", by substituting for the particulars relating to it the following particulars:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Natamycin	-	-	All preparations unless exempted	-	-	Natamycin when use as food additive in food";

(xvii) in the item "Potassium hydroxide", by substituting for the particulars relating to it the following particulars:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Potassium hydroxide	-	-	-	-	12% and over unless exempted	Under 12%, accumulators, batteries or when use as food additive in food";

(xviii) in the item "Sodium hydroxide", by substituting for the particulars relating to it the following particulars:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Sodium hydroxide	-	-	All preparations for therapeutic or diagnostic use	-	All preparations containing 12% and over other than those in Part I or exempted and subject to the provisions of Poisons (Sodium Hydroxide) Regulations 1962	Under 12%; sodium hydroxide when use as food additive in food";

(xix) by deleting the item "Terfenadine" and the particulars relating to it; and

(xx) by inserting after the item "Todrazoline; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Tofacitinib	-	All preparations"; and				

(b) in the Appendix to the Poisons List—

(i) in the list of "**Anticholinergics:**"—

(A) by inserting after the item "Diethazine; its salts" the item "Diphenidol hydrochloride"; and

(B) by inserting after the item "Methixene; its salts" the item "Mirabegron";

(ii) in the list of "**Antihistamines:**"—

(A) by inserting after the item "3-Dibutylaminomethyl-4, 5, 6-trihydroxy-1-isobenzofuranone" the item "Dimenhydrinate"; and

(B) by substituting for the item "Levocetrizine" the item "Levocetirizine";

(iii) in the list of "**Antineoplastic agents and Immunosuppressants:**"—

(A) by inserting after the item "Cabazitaxel" the item "Canakinumab";

(B) by inserting after the item "Carmustine; its salts" the item "Certolizumab";

(C) by inserting after the item "Idarubicin" the item "Infliximab"; and

(D) by inserting after the item "Tocilizumab" the item "Tofacitinib";

(iv) in the list of "**Cardio drugs:**"—

(A) by substituting for the item "Abrisentan" the item "Ambrisentan"; and

(B) by substituting for the item "Anistreplace" the item "Anistreplase";

(v) in the list of "**Industrial and laboratory poisons:**"—

(A) by inserting after the item "Acetyl chloride" the item "Alpha-Phenylacetoacetonitrile (APAAN)"; and

(B) by inserting after the item "Formaldehyde", the item "Gamma Butyrolactone";

(vi) in the list of "**Sympathomimetic amines:**", by inserting after the item "Atomoxetine; its salts" the item "1,3- Dimethylamylamine (DMAA)";

(vii) in the list of "**Tranquillisers:**", by substituting for the item "Amilsulpride" the item "Amisulpride"; and

(viii) in the list of "**Miscellaneous:**"—

(A) by substituting for the item "Calcium polysterene" the item "Calcium polystyrene"; and

(B) by substituting for the item "Lanthanum" the item "Lanthanum carbonate".

Made 26 January 2015
[KK(R)608(14); PN(PU2)172/XIII]

DATUK SERI DR. S. SUBRAMANIAM
Minister of Health